Janux Therapeutics, Inc. · NASDAQ:JANX
Janux Therapeutics — Technical Presentation (December 2025)
26 slides from Janux Therapeutics's technical presentation, Dec 1, 2025
Slide 1: Creating Transformative Medicines to Improve Patients' Lives
Creating Transformative Medicines to Improve Patients’ Lives JANX007 Phase 1 Clinical Update December 01, 2025
Slide 2: Forward-Looking Statements and Disclaimers
Forward-Looking Statements and Disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking sta
Slide 3: Evolving prostate cancer treatment landscape driving need for differentiated drugs
Evolving prostate cancer treatment landscape is driving a need for differentiated drugs to treat taxane-naïve mCRPC patients ~38k (Taxane-naïve mCRPC drug treated patients in US) Expanding Patient Segment 2018 >50% (First ARPi approved pre-mCRPC) (ARPi treated pre-mCRPC today) 5.6 - 9.3 months (rPFS
Slide 4: Key points for JANX007
Key points for JANX007 JANX007 is a first-in-class, first-in-human, tumor activated TCE (TRACTr) targeting human PSMA for the treatment of prostate cancer • JANX007 has achieved durable responses and rPFS with a manageable safety profile that compare favorably to both approved and investigational mC
Slide 5: JANX007 is a tumor-activated TCE being developed for prostate cancer
JANX007 is a tumor-activated TCE being developed for the treatment of prostate cancer • PSMA is a clinically validated, prostate cancer cell surface antigen that is highly apoptosis expressed in bone, lymph node and visceral metastases PSMA • TCEs targeting PSMA have demonstrated anti-tumor activity
Slide 6: Janux TRACTr platform design principles
Janux Tumor Activated T-Cell Engager (TRACTr) platform design principles Each program is designed as a potent T-cell engager with reduced toxicity Healthy Tissue Tumor Tissue TRACTr Design Healthy Tissue Masks block activity against healthy TCE is rapidly cleared from Tumor specific activation to ma
Slide 7: Ongoing JANX007 clinical studies designed to address key objectives
Ongoing JANX007 clinical studies have been designed to address key objectives to enable clinical development Objective Design Phase 1a mCRPC pts Select doses and regimen for Phase 1b studies Dose escalation and selected expansions to evaluate safety, efficacy and PK Dosing Regimen CRS mitigation Ide
Slide 8: Baseline subject characteristics
Baseline subject characteristics Heavily pretreated subjects with a median of 4 prior lines of therapy Dec2024 Subjectsⱡ All Subjects Characteristic n=16 n=109† Median age, years (range) 71.5 (54 – 79) 68 (46 – 86) Race, white / black / not reported / asian, % 88 / 6 / 6 / 0 75 / 15 / 8 / 2 ECOG PS
Slide 9: JANX007 has demonstrated encouraging durability in advanced-stage mCRPC patients
JANX007 has demonstrated encouraging durability in advanced-stage mCRPC patients PSA Best Response PSA50 PSA90 PSA99 Efficacy <PSA50 • Durable responses observed in subjects with bone only disease as Non-evaluable well as subjects with soft-tissue mets RECIST 1.1 • Clinical benefit persisted with tr
Slide 10: JANX007 has demonstrated promising rPFS in advanced-stage mCRPC patients
JANX007 has demonstrated promising rPFS in advanced-stage mCRPC patients All Subjects May 2025* - QW Expansion - QW Expansion - Q2W Radiographic PFS, (n) N = 108 N=9 N = 29 N = 19 Median rPFS, (months)† 7.3 7.9 7.9 8.9 Kaplan-Meier, Est. % 3 months 71 78 89 76 6 months 51 78 76 54 Efficacy rPFS %PFS
Slide 11: Manageable safety profile during dose exploration
Manageable safety profile during dose exploration Treatment related adverse events in ≥15% subjects All Subjects (n=109) Preferred Term Grade 1 Grade 2 Grade ≥3 All Grades Cytokine release syndrome 36 (33) 60 (55) 9 (8) 105 (96) Diarrhea 40 (37) 20 (18) 6 (6) 66 (61) CRS associated AEs* Nausea 34 (3
Slide 12: JANX007 achieved deep PSA reductions and RECIST responses
JANX007 treatment achieved deep PSA reductions and RECIST responses Best PSA Reduction RECIST Response* 75 Group (n) PSA50 PSA90 ORRⱡ Best % Change in Target Lesion Best PSA % Change from Baseline ≥2mg1 (n=85) 73% 26% ≥2mg2 (n = 27) 30% 50 Sum of Diameters 25 0 -25 -50 -75 -100 Target dose <2 mg Tar
Slide 13: Ongoing JANX007 clinical studies designed to address key objectives
Ongoing JANX007 clinical studies have been designed to address key objectives to enable clinical development Objective Design Phase 1a mCRPC pts Select doses and regimen for Phase 1b studies Dose escalation and selected expansions to evaluate safety, efficacy and PK Dosing Regimen CRS mitigation Ide
Slide 14: Optimized CRS-P2 mitigation procedure is associated with low grade CRS
Optimized CRS-P2 mitigation procedure is associated with low grade CRS Evaluate timing/dose of dexamethasone and/or tocilizumab December 2024 CRS-P1 CRS-P2 100 100 CRS profile and PSA redn 100 CRS profile improved, PSA inferior to Dec2024 redn similar to Dec2024 75 % of Subjects 75 75 % of Subjects
Slide 15: Ongoing JANX007 clinical studies designed to address key objectives
Ongoing JANX007 clinical studies have been designed to address key objectives to enable clinical development Objective Design Phase 1a mCRPC pts Select doses and regimen for Phase 1b studies Dose escalation and selected expansions to evaluate safety, efficacy and PK Dosing Regimen CRS mitigation Ide
Slide 16: Efficacy and safety evaluation with once-weekly dosing regimen
Efficacy and safety evaluation in subjects treated with once-weekly dosing regimen Comparison of later cycle efficacy and safety Efficacy Dose: 3 mg QW 6 mg QW 9 mg QW 12 mg QW • Evaluate rPFS and KM estimates to Efficacy N=5 N=11 N=6 N=5 prioritize target doses Median rPFSⱡ, (months) 7.0 Not reache
Slide 17: Efficacy and safety evaluation with Q2W dosing regimen
Efficacy and safety evaluation in subjects treated with Q2W dosing regimen Comparison of later cycle efficacy and safety Efficacy Dose and regimen: 6 & 9 mg QW 6 & 9 mg Q2W • Evaluate rPFS and KM estimates to compare QW Efficacy* N=17 N=14 and Q2W Median rPFSǂ, (months) 7.9 8.9 Safety Kaplan-Meier,
Slide 18: Ongoing JANX007 clinical studies designed to address key objectives
Ongoing JANX007 clinical studies have been designed to address key objectives to enable clinical development Objective Design Phase 1a mCRPC pts Select doses and regimen for Phase 1b studies Dose escalation and selected expansions to evaluate safety, efficacy and PK Dosing Regimen CRS mitigation Ide
Slide 19: Early snapshot of efficacy and CRS in Phase 1b taxane-naïve patients
Early snapshot of efficacy and CRS in Phase 1b taxane-naïve patients P1b taxane-naïve Patients receiving 6mg QW dose regimen Best PSA % Change from Baseline 0 100 Status 75 • Dosing ongoing, subjects in early % of Subjects -25 dosing cycles* * 50 • Focus upon PSA reductions and CRS -50 PSA50 Efficac
Slide 20: JANX007 rPFS durability correlates with disease burden
JANX007 rPFS durability correlates with disease burden Analysis based upon surrogate clinical markers of disease burden Disease burden and rPFS Disease burden and stage Objective 100 100 • Evaluate impact of disease burden on rPFS rPFS Probability 10.5mo (24pts) 75 rPFS % of Subjects • Disease burde
Slide 21: Phase 1a studies provide favorable basis for Phase 1b and pivotal studies
Phase 1a studies with JANX007 provide favorable basis for Phase 1b and pivotal studies Objective Outcome Phase 1a mCRPC pts Select doses and regimen for Phase 1b studies Doses and regimens have been identified Dosing Regimen CRS mitigation Identify easy to follow protocol that maintains CRS-P2 m
Slide 22: Clinical Development Planning
Clinical Development Planning
Slide 23: Clinical development plans and considerations for JANX007 in the pre-taxane setting
Clinical development plans and considerations for JANX007 in the pre-taxane setting Clinical Plans • JANX007 monotherapy and in combination with darolutamide in taxane naïve, pre-Pluvicto mCRPC patients • Largest and growing mCRPC setting due to increased use of ARPi’s in HSPC • Will also evaluate i
Slide 24: TCEs have demonstrated a more prolonged OS than predicted based upon rPFS
TCEs have demonstrated a more prolonged OS than predicted based upon rPFS Pluvicto has consistently demonstrated a less durable OS than predicted based upon rPFS Treatments and Indication rPFS (mo) OS (mo) Ratio Drug Control Indication Drug Control ΔrPFS (mo) Drug Control ΔOS (mo) ΔOS/ΔrPFS TCEs Lim
Slide 25: Conclusions
Conclusions JANX007 is a first-in-class, first-in-human, tumor activated TCE (TRACTr) targeting human PSMA for the treatment of prostate cancer JANX007 has achieved durable responses and rPFS coupled with a manageable safety profile that compare favorably to both approved and investigational mCRPC
Slide 26: David Campbell, Ph.D.
JanuxRx.com David Campbell, Ph.D. President and CEO 10955 Vista Sorrento Parkway San Diego, CA 92130 dcampbell@januxrx.com
Janux Therapeutics — Technical Presentation (December 2025) on 6ix